ATE532524T1 - Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs - Google Patents

Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs

Info

Publication number: ATE532524T1
Authority: AT; Austria
Prior art keywords: polysaccharide; cancer; treatment; chemotherapeutic agent; simultaneous administration
Prior art date: 2001-03-27

Application number

AT02731178T

Other languages

English (en)

Inventor

Anatole Klyosov

David Platt

Original Assignee

Pro Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-27

Filing date

2002-03-27

Publication date

2011-11-15

2001-03-27 Priority claimed from US09/818,596 external-priority patent/US6645946B1/en

2002-03-27 Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE532524T1 publication Critical patent/ATE532524T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
150000004676 glycans Chemical class 0.000 title abstract 2
229920001282 polysaccharide Polymers 0.000 title abstract 2
239000005017 polysaccharide Substances 0.000 title abstract 2
239000002246 antineoplastic agent Substances 0.000 title 1
229940127089 cytotoxic agent Drugs 0.000 title 1
239000000203 mixture Substances 0.000 abstract 2
OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 abstract 1
229920000926 Galactomannan Polymers 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

AT02731178T 2001-03-27 2002-03-27 Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs ATE532524T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/818,596 US6645946B1 (en)	2001-03-27	2001-03-27	Delivery of a therapeutic agent in a formulation for reduced toxicity
US31709201P	2001-09-04	2001-09-04
PCT/US2002/009524 WO2002076474A1 (en)	2001-03-27	2002-03-27	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer

Publications (1)

Publication Number	Publication Date
ATE532524T1 true ATE532524T1 (de)	2011-11-15

Family

ID=26980760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02731178T ATE532524T1 (de)	2001-03-27	2002-03-27	Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs

Country Status (7)

Country	Link
US (1)	US7012068B2 (de)
EP (1)	EP1383516B1 (de)
JP (1)	JP4744782B2 (de)
AT (1)	ATE532524T1 (de)
DK (1)	DK1383516T3 (de)
ES (1)	ES2376739T3 (de)
WO (1)	WO2002076474A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6680306B2 (en) *	2001-06-21	2004-01-20	Glycogenesys, Inc.	Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) *	2003-04-07	2004-11-11	Glycogenesys, Inc.	Composition and uses of galectin antagonists
US20050053664A1 (en) *	2003-09-08	2005-03-10	Eliezer Zomer	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
JP5021309B2 (ja)	2003-10-16	2012-09-05	ステファンジョンラルフ	免疫調節性組成物およびその使用方法
AU2004296647B2 (en)	2003-12-12	2011-06-02	Taiyo Kagaku Co., Ltd.	Enteropathy ameliorating composition
CA2570570A1 (en) *	2004-06-22	2006-01-05	Pro-Pharmaceuticals, Inc.	Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
WO2006017417A2 (en) *	2004-08-02	2006-02-16	Pro-Pharmaceuticals, Inc.	Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2008011216A2 (en)	2006-05-16	2008-01-24	Pro-Pharmaceuticals, Inc.	Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
WO2011016811A1 (en) *	2009-08-07	2011-02-10	Pro-Pharmaceuticals, Inc.	Methods for reducing the incidence of chemotherapy - induced mucositis
US8604187B2 (en) *	2010-01-14	2013-12-10	North Texas Medical Associates	Compositions and methods of aloe polysaccharides
JP6055928B2 (ja)	2012-10-10	2016-12-27	ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物
US9339515B2 (en)	2013-02-20	2016-05-17	Galectin Therapeutics, Inc.	Method for treatment of pulmonary fibrosis
EP3813883A1 (de)	2018-06-29	2021-05-05	Glykos Biomedical Oy	Konjugate
US20230038373A1 (en)	2019-12-18	2023-02-09	Glykos Biomedical Oy	Stabile conjugate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118673A (en) *	1982-05-07	1992-06-02	Carrington Laboratories, Inc.	Uses of aloe products
US5308838A (en) *	1982-05-07	1994-05-03	Carrington Laboratories, Inc.	Uses of aloe products
WO1993008810A1 (en) *	1991-11-05	1993-05-13	Carrington Laboratories, Inc.	Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
JP3801658B2 (ja)	1993-03-02	2006-07-26	太陽化学株式会社	β−グルクロニダーゼ活性抑制組成物
GB9412394D0 (en)	1994-06-21	1994-08-10	Danbiosyst Uk	Colonic drug delivery composition
US5834442A (en) *	1994-07-07	1998-11-10	Barbara Ann Karmanos Cancer Institute	Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
WO1996004014A1 (fr)	1994-07-29	1996-02-15	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	Preparation de medicament a liberation lente
US5861142A (en) *	1996-03-25	1999-01-19	Schick; Mary Pichler	Method for promoting hair, nail, and skin keratinization
WO1998050018A1 (en) *	1997-05-06	1998-11-12	Xiao Yu Wu	Drug delivery system
AU749623B2 (en)	1998-03-26	2002-06-27	Astellas Pharma Inc.	Sustained release preparations
KR20000011247A (ko) *	1998-07-23	2000-02-25	김윤	다당류를이용한대장선택성약물전달조성물및약학제제
JP5068401B2 (ja)	1998-09-28	2012-11-07	カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ	Ｈｐｍｃカプセルを使用する腸及び結腸への送達
JP2002541092A (ja)	1999-04-06	2002-12-03	ファーマクエスト・リミテッド	メチルフェニデートのパルス性送達のための薬学的投薬形態

2002
- 2002-03-27 EP EP02731178A patent/EP1383516B1/de not_active Expired - Lifetime
- 2002-03-27 ES ES02731178T patent/ES2376739T3/es not_active Expired - Lifetime
- 2002-03-27 JP JP2002574987A patent/JP4744782B2/ja not_active Expired - Lifetime
- 2002-03-27 DK DK02731178.6T patent/DK1383516T3/da active
- 2002-03-27 AT AT02731178T patent/ATE532524T1/de active
- 2002-03-27 WO PCT/US2002/009524 patent/WO2002076474A1/en active Application Filing
- 2002-03-27 US US10/108,237 patent/US7012068B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US7012068B2 (en)	2006-03-14
US20030064957A1 (en)	2003-04-03
EP1383516B1 (de)	2011-11-09
JP2004525143A (ja)	2004-08-19
ES2376739T3 (es)	2012-03-16
EP1383516A4 (de)	2007-08-01
WO2002076474A1 (en)	2002-10-03
EP1383516A1 (de)	2004-01-28
JP4744782B2 (ja)	2011-08-10
DK1383516T3 (da)	2012-02-20

Publication	Publication Date	Title
ATE532524T1 (de)	2011-11-15	Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs
ATE322265T1 (de)	2006-04-15	Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
HK1066482A1 (en)	2005-03-24	Use os fucans in the treatment of adhesions, arthritis and psoriasis
GEP20053424B (en)	2005-01-25	Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
ATE328599T1 (de)	2006-06-15	Antitumorale mittel
ATE307608T1 (de)	2005-11-15	Kombination von doctaxel und rhumab her2 zür krebsbehandlung
GEP20063805B (en)	2006-04-25	Alkyne-Arylnaphthyridin-4-one as Phosphodiesterase-4 Inhibitors
TW200518752A (en)	2005-06-16	Combinations of drugs for the treatment of neoplasms
HUP0400231A3 (en)	2010-11-29	Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
ATE441423T1 (de)	2009-09-15	Verwendung von mastix und dessen ätherischen ílen zur verhinderung oder bekämpfung von mikrobieller infektionen
DE60124387D1 (de)	2006-12-21	Synergistische kombination zur behandlung von kolorektalkarzinom
DE60036915D1 (de)	2007-12-13	Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
WO2005025501A3 (en)	2005-05-19	Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1503748A4 (de)	2009-10-21	Arzneimittel zur linderung durch taxan induzierte neurotoxizität
EA200801731A1 (ru)	2009-10-30	Составы и способы лечения тробмоцитемии
ATE417608T1 (de)	2009-01-15	Arzneizusammensetzungen enthaltend modafinilverbindungen
UA83888C2 (ru)	2008-08-26	Фармацевтическая композиция винфлунина, предназначенная для парентерального введения, способ получения и применение
HK1068606A1 (en)	2005-04-29	Novel aminobenzoephenones
FR2846327B1 (fr)	2006-03-24	Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
ATE345805T1 (de)	2006-12-15	Calciumtrifluoracetat mit zytotoxischer wirkung
WO2002076393A3 (en)	2003-04-03	Antiagionecic, antitumor, chemopreventative agents
MXPA05013827A (es)	2006-03-13	Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.
AU2003285125A8 (en)	2004-05-25	Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
TW200500073A (en)	2005-01-01	Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
FR2812549B1 (fr)	2003-03-21	Associations dalfopristine/quinupristine avec le cefpirome